CK Life Sciences (HKG:0775) said it established a new subsidiary to advance its therapeutic cancer vaccine portfolio, according to a Hong Kong bourse filing Tuesday.
Sequencio Therapeutics will be responsible for research and development into the company's investigational vaccines with potential application in breast and colorectal cancer.